Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables - Net: 2009-2024

Historic Receivables - Net for Ani Pharmaceuticals (ANIP) over the last 14 years, with Dec 2024 value amounting to $221.7 million.

  • Ani Pharmaceuticals' Receivables - Net rose 28.65% to $252.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.6 million, marking a year-over-year increase of 28.65%. This contributed to the annual value of $221.7 million for FY2024, which is 36.80% up from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Receivables - Net is $221.7 million, which was up 36.80% from $162.1 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Receivables - Net ranged from a high of $221.7 million in FY2024 and a low of $95.8 million during FY2020.
  • Over the past 3 years, Ani Pharmaceuticals' median Receivables - Net value was $165.4 million (recorded in 2022), while the average stood at $183.1 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first declined by 2.03% in 2023, then spiked by 36.80% in 2024.
  • Ani Pharmaceuticals' Receivables - Net (Yearly) stood at $95.8 million in 2020, then surged by 34.17% to $128.5 million in 2021, then rose by 28.72% to $165.4 million in 2022, then dropped by 2.03% to $162.1 million in 2023, then surged by 36.80% to $221.7 million in 2024.